Kite, a subsidiary of Gilead Sciences, Inc. (GILD), announced data from a pilot study in collaboration with Dana-Farber Cancer Institute, which demonstrated toleration of Yescarta in patients with relapsed or refractory primary or secondary central nervous system lymphoma or CNSL.
The biotechnology company stated that CNSL is an aggressive and rare form of non-Hodgkin lymphoma that has either originated in or spread to the brain, eye, spinal cord, or cerebrospinal fluid.
In the study, conducted on 18 patients, the response rate was 94.4 percent and the complete response rate was 66.7 percent.
Currently, Gilead's stock is trading at $64, down 0.42 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Health News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.